In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litig., No. 18-md-2819 (E.D.N.Y.)
In the Restasis case, Faruqi & Faruqi represents a proposed class of direct purchasers of Restasis. The direct purchasers alleged that the drug's manufacturer, Allergan, Inc., delayed entry of a generic version of Restasis by procuring patents by fraud, ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.)
Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Actavis' Namenda XR, alleging that Actavis Actavis engaged in an illegal product hop to ...
Joseph T. Lukens, Peter Kohn at New York office
In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.)
In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer's blockbuster anti-inflammatory drug, Celebrex, alleging that Pfizer procured a patent ...
Joseph T. Lukens, Peter Kohn at New York office
In re Opana Antitrust Litig., No. 14-10150 (N.D. Ill.)
In the Opana case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo Pharmaceuticals' Oxymorphone ER, sold under the brand name Opana ER. The proposed class alleges that Endo and would-be generic ...
Joseph T. Lukens, Peter Kohn at New York office
In re Lidoderm Antitrust Litig., No. 14-2521 (N.D. Cal.)
In the Lidoderm case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo's 5% lidocaine patch, Lidoderm. The case alleges that Endo paid its would-be generic competitor, Watson (now known as Actavis) ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Aggrenox Antitrust Litig., No. 14-2516 (D. Conn.)
In the Aggrenox case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Boehringer Ingelheim's combination stroke prevention drug, Aggrenox. The case alleges that Boehringer paid its would-be generic competitors ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Solodyn Antitrust Litig., No. 14-10438 (D. Mass.)
In the Solodyn case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Medicis's minocycline drug, Solodyn. The case alleges that Medicis engaged in an anticompetitive scheme to prevent lower-priced generic ...
Neill W. Clark, Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Loestrin 24 Fe Antitrust Litig., No. 13-2472 (D.R.I.)
In re Loestrin 24 Fe Antitrust Litig., No. 13-2472 (D.R.I.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Warner Chilcott's oral contraceptive drug, Loestrin 24 Fe, alleging that Warner Chilcott ...
Neill W. Clark, Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Nexium (Esomeprazole) Antitrust Litigation, No. 1:12-md-02409-WGY (D. Mass.)
In Nexium, Faruqi & Faruqi, who filed the very first complaint on behalf of direct purchasers, represents a certified class of direct purchasers of the prescription drug Nexium. The direct purchaser class alleges that in the brand manufacturer, AstraZeneca, ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
Mylan Pharmaceuticals, Inc. v. Warner Chilcott Public Limited Company, et al. No. 12-3824 (E. D. Pa.)
In this case, nicknamed the Doryx case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of Warner-Chilcott's branded drug, Doryx (delayed-release doxycycline hyclate). The case alleges that Warner-Chilcott ...
Neill W. Clark, Peter Kohn at Pennsylvania office